Serum M-Protein

Biomarker

Related News

Daratumumab marks shift toward early intervention in smoldering multiple myeloma

May 05, 2026

FDA approval of daratumumab for high-risk smoldering multiple myeloma marks a shift from observation to early intervention. In a Phase II trial in earlier-stage disease, the overall response rate was 54% and the primary endpoint was not met.

Survey Reveals Real-World Bridging Therapy Practices for CAR T-Cell Therapy in Multiple Myeloma

Mar 31, 2026

A multinational survey shows bridging therapy is used for over 85% of multiple myeloma patients awaiting CAR T-cell therapy, with proteasome inhibitors being the most common approach. Most centers lack standardized protocols and typically bridge patients for 1-2 months, with regimen selection driven primarily by prior therapy history and disease burden.